The european organization for research and treatment of cancer quality of life questionnaire-BR 23 breast cancer-specific quality of life questionnaire: psychometric properties in a Moroccan sample of breast cancer patients

BMC Research Notes

Chakib Nejjari²  Rachid Bekkali³  Abdelatif Benider⁴  Hassan Errihani¹  Maria Bennani³  Ahmed Zidouh³  Karima Bendahhou²  Naima Abda²  Samira El Fakir² 

[1] National Institute of Oncology, Rabat, Morocco;Department of epidemiology and public health, Faculty of Medicine, University Sidi Mohammed Ben Abdellah, Fez, Morocco;Fondation Lalla Salma Prevention and Treatment of Cancers, Rabat, Morocco;Oncology Center Ibn Rochd, Casablanca, Morocco

关键词: Validity;    Reliability;    Quality of life;    Breast cancer;   

Others  :  1134741
DOI  :  10.1186/1756-0500-7-53

 received in 2013-06-05, accepted in 2014-01-07,  发布年份 2014

【 摘 要 】

Background

Quality of life (QOL) and its measurement in cancer patients is becoming increasingly important. Breast cancer diagnosis and treatment are often associated with psychological distress and reduced QoL. In Arabic-speaking countries, QoL of patients with cancer is inadequately studied.

The aim of this study was to test the reliability and validity of the Moroccan Arabic version of the European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer-Specific Quality of Life Questionnaire (QLQ-BR23).

Methods

After translation and cross-cultural adaptation, the questionnaire was tested on breast cancer patients. The participants’ number for the test and the retest were 105 and 37 respectively. Internal consistency was tested using Cronbach’s alpha coefficient (α), the test-retest reliability using intraclass correlation coefficients (ICC). Construct validity was assessed by examining item-convergent and divergent validity.

Results

The questionnaire was administered to 105 patients. The mean age of patients was 48 years (SD: 16), 62.9% were married. 68.6% of all participants lived in urban area.

The average time to complete the QLQ- BR23 was 15 min. Cronbach’s alpha coefficient, were all >0.7, with the exception of breast symptoms and arm symptoms. All items exceeded the 0.4 criterion for convergent validity except item 20 and 23 related to pain and skin problems in the affected breast respectively.

Conclusion

In general, the findings of this study indicated that the Moroccan Arabic version of the EORTC QLQ-BR23 is a reliable and valid supplementary measure of the QOL in breast cancer patients and can be used in clinical trials and studies of outcome research in oncology.

【 授权许可】

   
2014 El Fakir et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]World Health Organization: Cancer. 2006. http://www.who.int/mediacentre/factsheets/fs297/ webcite
• [2]World Health Organization International Agency for Research on Cancer World Cancer Report. 2003. Available at: http://www.iarc.fr/en/Publications/PDFs-online webcite
• [3]Globocan 2008(IARC) International Agency for Research on Cancer; section of cancer information. http://globocan.iarc.fr webcite
• [4]Montazeri A: Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974to 2007. J Expt Clin Cancer Res 2008, 27:32. BioMed Central Full Text
• [5]King MT, Fayers PM: Making quality-of-life results more meaningful for clinicians. Lancet 2008, 371(9614):709-710.
• [6]Sloan JA, Frost MH, Berzon R, Dueck A, Guyatt G, Moinpour C, Sprangers M, Ferrans C, Cella D: Clinical significance consensus meeting group the clinical significance of quality of life assessments in oncology: a summary for clinicians. Support Care Cancer 2006, 14:988-998.
• [7]Albert US, Koller M, Lorenz W, Kopp I, Heitmann C, Stinner B, Rothmund M, Schulz KD: Quality circle: quality of life profile: frommeasurement to clinical application. Breast 2002, 11:324-334.
• [8]Sprangers MA: Quality-of-life assessment in oncology.Achievements and challenges. Acta Oncol 2002, 41:229-237.
• [9]Aaronson NK, Ahmedzai S, Bergman B, et al.: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials inoncology. J Natl Cancer Inst 1993, 85:365-376.
• [10]Sprangers MA, Groendvold M, Arraras JI, et al.: The European Organization for Research and Treatment of Cancer cancer specific quality-of-life questionnairemodule: first results from a three country field study. J Clin Oncol 1996, 14:2756-2768.
• [11]Manal A, Awad A, Srdjan Denic B, Hakam Taji E: Validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires forArabic-speaking Populations. Ann. N.Y. Acad. Sci 2008, 1138:146-154.
• [12]Montazeri A, Harirchi I, Vahdani M, et al.: The EORTC breast cancer-specific quality of life questionnaire (EORTC QLQ-BR23): translation and validation study of the Iranian version. Qual. LifeRes 2000, 9:177-184.
• [13]Chie WC, Chang KJ, Huang CS, et al.: Quality of life of breast cancer patients in Taiwan: validation of the Taiwan Chinese version of the EORTC QLQ-C30 and EORTC-BR23. Psychooncology 2003, 12:729-735.
• [14]Kontodimopoulos N, Ntinoulis K, Niakas D: Validity of the Greek EORTC QLQ-C30 and QLQ-BR23 for measuring health-related quality of life in breast cancer patients. Eur J Cancer Care (Eng) 2011 May, 20(3):354-361.
• [15]Shafika A: Alawadi1 and Jude U Ohaeri*2. Health – related quality of life of Kuwaiti women with breast cancer: a comparative study using the EORTC Quality of Life Questionnaire. BMC Cancer 2009, 9:222. BioMed Central Full Text
• [16]Jayasekara H, Rajapaksa LC, Brandberg Y: Measuring breast cancer-specific health-related quality of life in South Asia: psychometric properties of the Sinhala version of the EORTC QLQ-BR23. Qual Life Res 2008, 17(6):927-932.
• [17]Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, Franzini L: Williams A, deHaes HC, Hopwood P, Cull A, Aaronson NK: The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country fieldstudy. J Clin Oncol 1996, 14:2756-2768.
• [18]Guillemin F, Bombardier C, Beaton D: Cross-cultural adaptation of health-related quality of life measures: Literature review and proposed guidelines. JClin Epidemiol 1993, 46(12):1417-1432.
• [19]Beaton D, Bombardier C, Guillemin F, Ferraz MB: Guidelines for the process of cross-cultural adaptation of self-report measures. SPINE 2000, 25(24):3186-3191.
• [20]Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D: Bottomley A, on behalf of the EORTC Quality of Life Group: The EORTC QLQ – C30 Scoring Manual 3rd edition. European Organization for Research and Treatment of Cancer: Brussels; 2001.
• [21]Cronbach LJ: Coefficient alpha and the internal structure of tests. psychometrika 1951, 16:297-334.
• [22]Hays RD, Hayashi T, Carson S, Ware JE: User’s Guide for the Multitrait Analysis Program (MAP). Santa Monica, CA: Rand Corporation; 1988.
• [23]Streiner DL, Norman GR: Health measurment scales. Apractical guide to their development and use. Third edition ed. Oxford: Oxford university press; 2003.
• [24]Montazeri A, Harirchi I, Vahdani M, et al.: The EORTC breast cancer-specific quality of life questionnaire (EORTC QLQ-BR23): translation and validation study of the Iranian version. Qual. Life Res 2000, 9:177-184.
• [25]Kyriaki M, Eleni T, Efi P, et al.: The EORTC Core Quality of Life questionnaire (QLQ-C30, version 3.0) in terminally ill cancer patients under palliative care: validity and reliability in a Hellenic sample. Int. J Cancer 2001, 94:135-139.
• [26]Awad MA, Denic S, El Taji H: Validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires for Arabic-speaking Populations. Ann. N.Y Acad. Sci 2008, 1138:146-154.
• [27]Montazeri A, Harirchi I, Vahdani M, et al.: The EORTC breast cancer-specific quality of life questionnaire (EORTC QLQ-BR23): translation and validation study of the Iranian version. Qual. Life Res 2000, 9:177-184.